The Federal Circuit has ruled that Sandoz did not forfeit its preemption defence and the BPCIA preempts state law remedies in its biosimilars dispute with Amgen. The decision makes clear that brand biologic companies have no remedies available against a biosimilar applicant who is refusing to engage in the patent dance
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
On day one of the EUIPO’s Case Law Conference, delegates heard why single-letter trademarks are weak and received an update on the EU’s design law shakeup
High-earning businesses place most value on the depth of the external legal teams advising them, according to a survey of nearly 29,000 in-house counsel
In-house lawyers have considerable influence over law firms’ actions, so they must use that power to push their external advisers to adopt sustainable practices